What SBC Medical Group Holdings, Inc. told the SEC could break it.

Substantially all of SBC's long-lived assets and revenues are attributable to its operations in Japan (with small footprints in Singapore/Vietnam/US), concentrating it in the Japanese cosmetic-medicine market and economy.

“substantially all of our long-lived assets and revenues generated were attributed to the Company's operations in Japan.”

SBC generates a substantial majority of revenue from management services to its affiliated Medical Corporations (MCs) — related parties such as Shobikai (~$41M) and Kowakai (~$37M) — so its revenue is highly concentrated in, and dependent on, a small set of related-party franchise clinics.

“The Company generates a substantial majority of its revenue from provision of management services to the MCs pursuant to the franchisor-franchisee agreements and/or service agreements.”

SBC depends substantially on key management — notably CEO Yoshiyuki Aikawa, who has deep cosmetic-clinic-industry experience and is also a counterparty in related-party transactions — so loss of key personnel could materially harm the business.

“We rely on our executive officers, senior management and key employees to generate business and execute our initiatives successfully. Yoshiyuki Aikawa, our Chief Executive Officer, has a wealth of knowledge and business experience in the cosmetic clinic industry and the related management services”

SBC's revenue depends on the MCs' compliance with Japanese regulation — the Medical Care Act, APPI privacy law, Antimonopoly Act and Poisonous & Deleterious Substances Control Act — so an MC's non-compliance would harm the franchised brand and directly reduce SBC's management-service revenue.

“A failure by the MCs or other independently operated clinics to comply with the Medical Care Act may harm our franchised brand and directly result in a reduction of the Company's revenue, since we receive substantial revenue from the MCs as part of our compensation for management services.”